Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985718 | 0.84 | CYP2A6 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17795981 | 0.83 | CYP2A6 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL144441 | 0.81 | CYP2A6 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6248129 | 0.80 | CYP2A6 (0.63) | CYP2A6CYP1A2MAPTTDP1ALDH1A1 | |
| SCHEMBL12134542 | 0.79 | HDAC3 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8189102 | 0.79 | SMN1; SMN2 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12796847 | 0.78 | BCL2L1 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12796846 | 0.78 | BCL2L1 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL144486 | 0.77 | ALDH1A1 (0.38) | CYP2A6MAPTRAB9AESR1ESR2 | |
| SCHEMBL5241572 | 0.77 | ESR2 (0.58) | CYP1A2ESR1ESR2GAADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043749-B2 | Method for producing ink composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-07-23 | — | — | US | disclosed |
| US-12043749-B2 | Method for producing ink composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-07-23 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11917839-B2 | High signal-to-noise ratio photoelectric conversion element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11917839-B2 | High signal-to-noise ratio photoelectric conversion element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20240023422-A1 | COMPOSITION, FILM, ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, AND PHOTODETECTION ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240023422-A1 | COMPOSITION, FILM, ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, AND PHOTODETECTION ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-01-18 | — | — | US | disclosed |
| US-11877459-B2 | Light detecting element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11877459-B2 | Light detecting element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-01-16 | — | — | US | disclosed |
| WO-2023238764-A1 | COMPOSITION, FILM, ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, AND PHOTODETECTION ELEMENT | 住友化学株式会社 | 2023-12-14 | — | — | WO | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | WILEY MICHAEL R | 2007-03-29 | — | — | US | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7169931-B2 | Cell differentiation, cell proliferation | SHIONOGI & CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20060091364-A1 | Photocontrolled photochromic electroluminescent and electroconductive polymers for photonics | SAMSUNG DISPLAY CO., LTD. (KR) | 2006-05-04 | — | — | US | disclosed |
| WO-2006041831-A2 | CYCLIC Β-AMINO ACID DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004108892-A2 | 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004031145-A2 | LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | F2, F11, F12 | HDAC3 4106/4885HDAC4 4577/4885HDAC1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.